Abbott (NYSE:ABT) today highlighted significant growth within its Diabetes business amid its fourth-quarter results for 2024.

Blood sugar tracking is officially general-wellness territory. Abbott announced Thursday that its prescription-free ...

Abbott's diabetes care business executive vice-president ... While the financial terms and commercial availability timeline ...

While the pandemic caused some of ... commercial success of its Libre franchise, which includes planned expansions to tap into new patient populations such as people without diabetes who wish ...

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products ...

Litigation between the rival diabetes management operations has been going on since June 2021 with Dexcom and Abbott's diabetes division serving patent infringement complaints against each other ...

Divisional Vice President of Research and Development within global healthcare company Abbott’s diabetes care business. “Look at the popularity of DNA tests and wearables – personalised data ...